Features

What is on the industry’s radar for 2024?  See what issues make DCAT Value Chain Insights’ list—more established trends and those that may be under the industry’s radar: from growth prospects in the bio/pharma market, to key factors shaping drug development, and what may on the horizon for manufacturing and the supply chain.

The European Commission has launched the Critical Medicines Alliance, an EU-level initiative to develop recommendations and provide advice to EU policy decision-makers on how to address long-standing medicines shortages, including ways to shore up domestic manufacturing in the EU and strengthen the bio/pharma supply chain.

What can CDMOs/CMOs expect in 2024? DCAT Value Chain Insights examines key trends, fundamentals, and the variables influencing the sector’s performance.

At the J.P. Morgan Annual Healthcare Conference in San Francisco this week, bio/pharma industry executives outlined their key pipeline contenders and commercial products. How do mergers and acquisitions play in their strategies?

What are the Top 10 items in the bio/pharma industry to watch for in 2024? From blockbusters in the making, to moderating industry growth, to patent & drug pricing reforms, to moves to shore up the supply chain, DCAT Value Chain Insights examines what will shape the industry this year.

The FDA is seeking industry feedback by mid-February on a new program to facilitate innovation in pharmaceutical manufacturing and related technologies to improve the reliability and robustness of manufacturing processes and the supply chain. What does the proposed new program entail?

Pfizer’s $43-billion acquisition of Seagen was the deal of the year in 2023, but will it be enough for Pfizer’s Chairman & CEO Albert Bourla as the company seeks to offset declining sales for its COVID-19 products? What will be the key products for Pfizer to retain its number one industry revenue ranking in 2024?

The European Commission, the Heads of Medicines Agencies, and the European Medicines Agency have published the first version of the EU’s list of critical medicines for which the EU is prioritizing continuity of supply. What active pharmaceutical ingredients made the list, and what is the impact on API manufacturers?

As 2023 comes to a close, what were the largest mergers and acquisitions and expansions made by CDMOs/CMOs in 2023? DCAT Value Chain Insights looks at which companies topped the headlines this year and the leading moves they made.

A study by DCAT is gaining input from senior executives in the Bio/Pharma industry on the potential and current use of artificial intelligence (AI) in supply-chain management. Where does Bio/Pharma stand? Provide your company’s input by December 20, 2023.